The startup is expanding its services less than one year after it started offering compounded GLP-1 weight loss drugs.

The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.

Hims & Hers Health, Inc. stock surged 1,000% with strategic growth, but high valuation & short interest suggest taking ...

Hims & Hers Health shares swooned after the Food & Drug Administration said the active ingredient in Ozempic and Wegovy is no ...

Hims & Hers Health, Inc. (NYSE:HIMS) announced the acquisition of a California-based peptide facility to enhance its domestic ...

Hims & Hers Health (HIMS) stock falls as the FDA declares that Novo Nordisk's (NVO) weight loss therapies are no longer in ...

Shares of Hims & Hers Health (NYSE: HIMS) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost as ...

Hims & Hers Health Inc. has acquired a California-based manufacturing facility to expand its range of peptide treatments, ...

HIMS stock plunged by 18% after the FDA news that resolved a shortage of weight-loss drugs like Ozempic and Wegovy, which ...

The U.S. FDA has officially declared that Novo Nordisk’s (NVO) popular diabetes and weight loss therapies, Ozempic and Wegovy ...

Hims & Hers Health (NYSE:HIMS – Get Free Report) is projected to announce its earnings results after the market closes on ...